PEB.NZ - Pacific Edge Limited

NZSE - NZSE Delayed Price. Currency in NZD

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800
http://www.pacificedge.co.nz

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. David DarlingCEO, MD & Exec. DirectorN/AN/AN/A
Ms. Kate RankinChief Financial OfficerN/AN/AN/A
Dr. Jimmy SuttieSr. VP of Global OperationsN/AN/AN/A
Dr. Parry Guilford Ph.D.Chief Scientific Officer & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Jack AtchasonSr. VP of Sales & Customer Service, Pacific Edge Diagnostics USA LimitedN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NZD.

Description

Pacific Edge Limited, a cancer diagnostic company, develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a suite of non-invasive laboratory tests for the deduction and management of bladder cancer. It is also developing Cxbladder Resolve, a product designed to identify high grade or late stage bladder cancer and provide increased clinical resolution; and Cxcolorectal (prognosis Gen II), a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers, which are in clinical and user trials. In addition, the company is developing products for gastric, melanoma, and endometrial cancers, which are in pre-clinical trials. Pacific Edge Limited was founded in 2001 and is headquartered in Dunedin, New Zealand.

Corporate Governance

Pacific Edge Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.